TrialHaematologica2012

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.

Deborah L White et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.